User menu

Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison

Bibliographic reference Vanhoutte, Els K ; Draak, Thomas H P ; Gorson, Kenneth C ; van Nes, Sonja I ; Hoeijmakers, Janneke G J ; et. al. Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison. In: Journal of the peripheral nervous system, Vol. 20, no.3, p. 289-295 (2015)
Permanent URL
  1. Andrich, Rasch Models for Measurement: RUMM2030 (2010)
  2. Arnould Carlyne, Vandervelde Laure, Batcho Charles Sèbiyo, Penta Massimo, Thonnard Jean-Louis, Can manual ability be measured with a generic ABILHAND scale? A cross-sectional study conducted on six diagnostic groups, 10.1136/bmjopen-2012-001807
  3. Beaton Dorcas E., Boers Marteen, Wells George A., Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research : , 10.1097/00002281-200203000-00006
  4. van der Beek N.A.M.E., Hagemans M.L.C., van der Ploeg A.T., van Doorn P.A., Merkies I.S.J., The Rasch-built Pompe-specific Activity (R-PAct) scale, 10.1016/j.nmd.2012.10.024
  5. Copay Anne G., Subach Brian R., Glassman Steven D., Polly David W., Schuler Thomas C., Understanding the minimum clinically important difference: a review of concepts and methods, 10.1016/j.spinee.2007.01.008
  6. Draak T. H. P., Vanhoutte E. K., van Nes S. I., Gorson K. C., Van der Pol W. L., Notermans N. C., Nobile-Orazio E., Leger J.-M., Van den Bergh P. Y. K., Lauria G., Bril V., Katzberg H., Lunn M. P. T., Pouget J., van der Kooi A. J., Hahn A. F., Doorn P. A. v., Cornblath D. R., van den Berg L. H., Faber C. G., Merkies I. S. J., , Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness, 10.1212/wnl.0000000000001044
  7. Eftimov, Cochrane Database Syst Rev, 1, CD001797 (2009)
  8. Heesch K., Masse L., Dunn A., Using Rasch modeling to re-evaluate three scales related to physical activity: enjoyment, perceived benefits and perceived barriers, 10.1093/her/cyl054
  9. Hobart J, Cano S, Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods, 10.3310/hta13120
  10. Hobart Jeremy C, Cano Stefan J, Zajicek John P, Thompson Alan J, Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations, 10.1016/s1474-4422(07)70290-9
  11. Hughes Richard AC, Donofrio Peter, Bril Vera, Dalakas Marinos C, Deng Chunqin, Hanna Kim, Hartung Hans-Peter, Latov Norman, Merkies Ingemar SJ, van Doorn Pieter A, Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial, 10.1016/s1474-4422(07)70329-0
  12. Hughes, Cochrane Database Syst Rev, 6, CD002063 (2010)
  13. Jaeschke Roman, Singer Joel, Guyatt Gordon H., Measurement of health status, 10.1016/0197-2456(89)90005-6
  14. Liang, J Rheumatol, 22, 1191 (1995)
  15. Lin Keh-chung, Fu Tiffany, Wu Ching-yi, Hsieh Ching-ju, Assessing the Stroke-Specific Quality of Life for Outcome Measurement in Stroke Rehabilitation: Minimal Detectable Change and Clinically Important Difference, 10.1186/1477-7525-9-5
  16. Merbitz, Arch Phys Med Rehabil, 70, 308 (1989)
  17. Merkies I.S.J., Lauria G., 131st ENMC International workshop: Selection of Outcome Measures for Peripheral Neuropathy Clinical Trials, 10.1016/j.nmd.2005.12.003
  18. Merkies I. S. J., van Nes S. I., Hanna K., Hughes R. A. C., Deng C., Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance, 10.1136/jnnp.2009.194324
  19. Neely J. Gail, Karni Ron J., Engel Samuel H., Fraley Patrick L., Nussenbaum Brian, Paniello Randal C., Practical guides to understanding sample size and minimal clinically important difference (MCID), 10.1016/j.otohns.2006.11.001
  20. van Nes Sonja I., Faber Catharina G., Merkies Ingemar S. J., Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials, 10.1111/j.1529-8027.2008.00169.x
  21. van Nes S. I., Vanhoutte E. K., van Doorn P. A., Hermans M., Bakkers M., Kuitwaard K., Faber C. G., Merkies I. S. J., Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies, 10.1212/wnl.0b013e318208824b
  22. Nobile-Orazio Eduardo, Cocito Dario, Jann Stefano, Uncini Antonino, Beghi Ettore, Messina Paolo, Antonini Giovanni, Fazio Raffaella, Gallia Francesca, Schenone Angelo, Francia Ada, Pareyson Davide, Santoro Lucio, Tamburin Stefano, Macchia Roberta, Cavaletti Guido, Giannini Fabio, Sabatelli Mario, Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial, 10.1016/s1474-4422(12)70093-5
  23. Norman Geoffrey R., Sloan Jeff A., Wyrwich Kathleen W., Interpretation of Changes in Health-related Quality of Life : The Remarkable Universality of Half a Standard Deviation, 10.1097/01.mlr.0000062554.74615.4c
  24. Nunnally, Psychometric Theory (1978)
  25. Rasch, Probabilistic Models for Some Intelligence and Attainment Tests (1960)
  26. van Schaik Ivo N, Eftimov Filip, van Doorn Pieter A, Brusse Esther, van den Berg Leonard H, van der Pol W Ludo, Faber Catharina G, van Oostrom Joost CH, Vogels Oscar JM, Hadden Rob DM, Kleine Bert U, van Norden Anouk GW, Verschuuren Jan JGM, Dijkgraaf Marcel GW, Vermeulen Marinus, Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial, 10.1016/s1474-4422(10)70021-1
  27. Shaw, Rasch Measurement Transactions, 6, 225 (1992)
  28. Sloan Jeff A., Cella David, Frost Marlene H., Guyatt Gordon H., Sprangers Mirjam A.G., Symonds Tara, Assessing Clinical Significance in Measuring Oncology Patient Quality of Life: Introduction to the Symposium, Content Overview, and Definition of Terms, 10.4065/77.4.367
  29. Sterne J. A C, Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methods, 10.1136/bmj.322.7280.226
  30. Tennant Alan, Conaghan Philip G., The Rasch measurement model in rheumatology: What is it and why use it? When should it be applied, and what should one look for in a Rasch paper?, 10.1002/art.23108
  31. Vanhoutte Els K., Hermans Mieke C. E., Faber Catharina G., Gorson Kenneth C., Merkies Ingemar S. J., Thonnard Jean-L., , Rasch-ionale for neurologists : Vanhoutte et al, 10.1111/jns.12122
  32. Vanhoutte Els Karla, Faber Catharina Gerritdina, van Nes Sonja Ingrid, Jacobs Bart Casper, van Doorn Pieter Antoon, van Koningsveld Rinske, Cornblath David Reid, van der Kooi Anneke Jelly, Cats Elisabeth Aviva, van den Berg Leonard Hendrik, Notermans Nicolette Claudia, van der Pol Willem Lodewijk, Hermans Mieke Catharina Elisabeth, van der Beek Nadine Anna Maria Elisabeth, Gorson Kenneth Craig, Eurelings Marijke, Engelsman Jeroen, Boot Hendrik, Meijer Ronaldus Jacobus, Lauria Giuseppe, Tennant Alan, Merkies Ingemar Sergio José, Modifying the Medical Research Council grading system through Rasch analyses, 10.1093/brain/awr318
  33. Vanhoutte Els K., Faber Catharina G., Merkies Ingemar S.J., 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands, 10.1016/j.nmd.2013.06.006
  34. W.H.O, The International Classification of Functioning, Disability and Health (ICF) (2010)
  35. Wright, Best Test Design (1979)